List of Excipients in Branded Drug TRIPLE ANTIBIOTIC

« Back to Dashboard

Generic Drugs Containing TRIPLE ANTIBIOTIC

Company	Ingredient	NDC	Excipient
Phoenix Pharmaceutical Inc	neomycin sulfate, polymyxin b sulfate and bacitracin zinc	57319-343	MINERAL OIL
Phoenix Pharmaceutical Inc	neomycin sulfate, polymyxin b sulfate and bacitracin zinc	57319-343	PETROLATUM
Phoenix Pharmaceutical Inc	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	57319-344	MINERAL OIL
Phoenix Pharmaceutical Inc	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	57319-344	PETROLATUM

What are the Most Frequently-Used Excipients in TRIPLE ANTIBIOTIC?

# Of NDCs	Excipient
1	MINERAL OIL
1	PETROLATUM

Triple Antibiotic Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Triple antibiotic products are topical OTC preparations combining bacitracin zinc, neomycin sulfate, and polymyxin B sulfate. The core commercial opportunity is not new antibiotic chemistry. It is better tolerability, improved skin feel, differentiated delivery, packaging, adherence, and lower-allergen formulations.

The product category has limited conventional patent leverage because the active ingredients and basic ointment concepts are longstanding. Competitive advantage is more likely to come from formulation know-how, trademark protection, packaging, manufacturing controls, consumer positioning, and regulatory execution.

What is Triple Antibiotic and which active ingredients does it contain?

Triple antibiotic is a product category rather than a single globally standardized drug. In the U.S., common formulations contain:

Active ingredient	Typical function	Representative concentration
Bacitracin zinc	Gram-positive antibacterial activity	400 units/g
Neomycin sulfate	Broad antibacterial activity	5 mg/g
Polymyxin B sulfate	Activity against many Gram-negative organisms	5,000 units/g

Commercial products may use ointments, creams, sprays, powders, or single-use packets. The most established U.S. format is an anhydrous petrolatum-based ointment. Product labels generally indicate use for minor cuts, scrapes, and burns and do not support treatment of deep wounds, serious infections, animal bites, or extensive burns [1].

Triple antibiotic products are topical first-aid products, not systemic antibiotics. The formulation is intended to deliver active ingredients to the superficial skin surface while limiting systemic exposure.

What excipients are used in Triple Antibiotic formulations?

The excipient system depends on dosage form and brand. Representative ointments use a hydrophobic base consisting primarily of white petrolatum or a petrolatum blend. Some branded products include additional oils, antioxidants, or botanical-derived lipids.

Representative excipient classes

Excipient class	Common examples	Primary formulation role
Occlusive base	White petrolatum, mineral oil	Forms a protective film and reduces water loss
Emollient	Vegetable oils, cocoa butter, lanolin derivatives	Improves spreadability and skin feel
Structuring agent	Microcrystalline wax, paraffin, fatty alcohols	Controls consistency and physical stability
Antioxidant	Tocopherols, sodium pyruvate	Limits oxidative degradation
Humectant	Glycerin, propylene glycol	Increases water retention in creams and gels
Emulsifier	Glyceryl stearate, polysorbates, cetearyl alcohol	Stabilizes oil-in-water creams
Preservative	Phenoxyethanol, parabens, organic acids	Controls microbial growth in water-containing systems
Chelator	Disodium EDTA	Binds trace metals and improves preservative or oxidation control
Propellant	Hydrocarbon or compressed gas systems	Enables aerosol or spray delivery

Anhydrous ointments have a major excipient advantage: they generally require less conventional preservation than water-containing creams. Their principal risks are physical instability, active distribution, package interaction, and consumer dislike of greasiness.

Water-containing creams create more room for sensory differentiation but require tighter control of microbial quality, preservative performance, pH, emulsion stability, and active compatibility.

Which excipient strategy is best for Triple Antibiotic?

The most commercially practical strategy is a segmented platform rather than a single universal formulation.

1. Anhydrous petrolatum ointment

This format remains the lowest-complexity and lowest-cost option. A petrolatum base provides occlusion, wound protection, and long shelf life. It is suitable for tubes, foil packets, and unit-dose sachets.

Key development priorities are:

• Uniform dispersion of the three antibiotics.
• Control of zinc salt sedimentation or agglomeration.
• Consistent extrusion from the package.
• Reduced tack and greasy after-feel.
• Compatibility with laminated tubes and plastic containers.
• Protection from heat-driven phase separation.

A differentiated ointment could use a lighter hydrocarbon blend, silicone-compatible emollients, or a structured semi-solid system that reduces drag during application. Any change must preserve active potency, content uniformity, stability, and monograph-compliant labeling.

2. Water-in-oil ointment or cream

A water-in-oil system can retain the occlusive behavior of an ointment while improving spreadability and washability. This format may appeal to consumers who reject traditional petrolatum products.

The main technical challenge is that water introduces microbial and physical stability risks. The manufacturer must establish:

• Preservative effectiveness.
• Emulsion stability under accelerated conditions.
• Active partitioning between phases.
• pH stability.
• Container compatibility.
• Microbial limits through shelf life.

This format has stronger differentiation potential than a conventional petrolatum ointment but carries higher manufacturing and regulatory execution risk.

3. Oil-in-water cream

An oil-in-water cream offers a lighter cosmetic profile and easier cleanup. It may be attractive for frequent household use, pediatric caregivers, and consumers who avoid greasy products.

The formulation must manage the water solubility and ionic character of the antibiotic salts. Surfactants, electrolytes, pH modifiers, and preservatives can alter viscosity, emulsion structure, or active stability.

A successful cream would need to demonstrate that improved sensory performance does not reduce active availability at the wound surface.

4. Hydrogel or film-forming system

A hydrogel could provide cooling, low residue, and better visibility of the wound. A film-forming spray or liquid could support no-touch application.

These formats create opportunities for proprietary delivery systems, but they also increase development complexity. The formulation must avoid excessive drying, stinging, occlusion, or interference with wound healing. Film-forming polymers must be screened for compatibility with the three active ingredients and with common wound exudate conditions.

5. Spray and powder products

Sprays can address no-touch application and institutional first-aid use. Powders may appeal to moisture-control applications but raise inhalation and dosing concerns.

The commercial case for these products depends on a defined use setting. A spray for hard-to-reach areas, a unit-dose product for travel, and a powder for occupational first-aid kits would have different packaging and label requirements.

What formulations are protected by Triple Antibiotic patents?

The active ingredient combination has limited apparent patent strength because bacitracin, neomycin, and polymyxin B are legacy antibiotics with long histories of use. Basic combinations of the three agents and conventional petrolatum vehicles are unlikely to support meaningful new-chemical-entity exclusivity.

Potentially protectable subject matter includes:

• Novel ratios of the three antibiotics.
• Low-allergen or impurity-controlled active grades.
• Specific particle-size distributions.
• Homogeneous dispersion methods.
• Stable water-containing emulsions.
• Preservative-free aqueous systems.
• Film-forming delivery systems.
• Single-use packaging with improved stability.
• Manufacturing processes that reduce potency loss.
• Formulations that control neomycin-related degradation.
• Specific combinations with barrier-repair ingredients.
• Reduced-sensitization formulations using alternative excipients.

A formulation patent would need to claim more than the presence of familiar antibiotics in a familiar ointment base. Stronger claims would link a defined composition to measurable technical results, such as improved stability, reduced irritation, improved content uniformity, or controlled release.

What is the FDA regulatory status of Triple Antibiotic?

In the United States, topical antibiotic first-aid products are generally regulated through the FDA OTC monograph framework rather than a conventional NDA, provided the product complies with applicable conditions.

The FDA’s topical antimicrobial framework addresses active ingredients, permitted uses, labeling, manufacturing, and other conditions for OTC marketing [2]. Product-specific labels are available through DailyMed and identify active ingredients, inactive ingredients, warnings, directions, and package configurations [1].

Regulatory priorities

A new Triple Antibiotic formulation would typically require assessment of:

• Active ingredient identity and concentration.
• Compliance with applicable OTC monograph conditions.
• Product quality and content uniformity.
• Stability and expiration dating.
• Microbial limits.
• Preservative effectiveness for aqueous products.
• Container-closure integrity.
• Labeling and first-aid directions.
• Irritation and sensitization risk.
• Manufacturing controls under 21 C.F.R. parts 210 and 211.

A meaningful formulation change may require a new regulatory assessment even when the active ingredients remain unchanged. The regulatory burden is usually greater for a cream, gel, spray, or preservative-free aqueous product than for a conventional anhydrous ointment.

What is the Orange Book status of Triple Antibiotic?

Triple Antibiotic OTC products generally do not have the same Orange Book patent-listing profile as prescription drugs approved under an NDA. The Orange Book primarily catalogs approved prescription products and certain approved OTC products, along with therapeutic equivalence information and listed patents where applicable [3].

For a monograph-compliant OTC topical product:

• There is generally no conventional NDA patent estate to list.
• Paragraph IV litigation is not the normal competitive pathway.
• Generic competition can arise through other OTC monograph-compliant products.
• Brand protection usually depends on trademarks, trade dress, manufacturing know-how, and distribution.

The absence of a conventional Orange Book strategy does not eliminate intellectual-property value. It shifts the value toward formulation patents, package design, trademarks, confidential process controls, and consumer recognition.

When does Triple Antibiotic lose exclusivity?

The core antibiotic combination has effectively lost composition-of-matter exclusivity. Bacitracin, neomycin, and polymyxin B are established active ingredients, and basic topical combinations have been commercially available for decades.

There is no single relevant patent expiration date for the category. Exclusivity must be analyzed by asset:

Asset	Typical protection profile
Bacitracin, neomycin, polymyxin B	Legacy actives; no meaningful new-molecule exclusivity
Basic triple-antibiotic ointment	Generally weak patent position
Proprietary cream or gel	Potential formulation patents
Unit-dose packaging	Potential design or utility patents
Brand name and trade dress	Trademark and unfair-competition protection
Manufacturing process	Trade-secret protection and possible process patents
Monograph-compliant product	Regulatory access without conventional NDA exclusivity

A company launching a competing OTC product would usually face a lower barrier than a company entering a patented prescription formulation. The principal barriers are product quality, brand distribution, retailer access, consumer trust, and compliance execution.

Which companies compete in the Triple Antibiotic market?

The competitive landscape includes branded consumer-health companies, private-label manufacturers, generic OTC manufacturers, hospital-supply suppliers, and contract manufacturers.

The best-known branded segment includes Neosporin and related triple-antibiotic products. Neosporin is associated with Kenvue following the separation of Johnson & Johnson’s consumer-health business [4]. Generic and store-brand products compete on price, package size, active-ingredient equivalence, and retail placement.

Competitive differentiation typically uses:

• Branded versus private-label positioning.
• Ointment versus cream delivery.
• Large household tube versus unit-dose packet.
• Standard versus pain-relief variants.
• Adult household versus pediatric first-aid positioning.
• Retail versus institutional distribution.
• Domestic versus international formulation platforms.

No reliable public source generally isolates revenue for the Triple Antibiotic product alone. Kenvue reports at broader segment and brand-portfolio levels, so revenue exposure must be modeled from category share, retail scanner data, distribution, and estimated unit volume rather than company-reported product revenue [4].

What commercial opportunities exist for Triple Antibiotic excipients?

The strongest opportunities are formulation upgrades that solve recognizable consumer problems.

Lower-grease ointment

A lighter ointment could improve compliance and reduce transfer to clothing or bedding. The formulation would need to retain an occlusive film and support active stability.

Low-sensitization platform

Neomycin is associated with allergic contact dermatitis in some users. Bacitracin can also cause sensitization. A commercial product could target lower irritation through excipient selection, impurity control, reduced fragrance exposure, and clear allergen communication. The formulation cannot eliminate active-related sensitization risk solely through excipient changes.

Preservative-free unit-dose product

Anhydrous, single-use packaging can reduce contamination risk and support travel, first-aid kits, military use, and institutional supply. The business case depends on manufacturing cost and packaging throughput.

Barrier-repair combination

A product combining the antibiotic platform with skin-barrier support could target dry or compromised skin around minor injuries. Candidate excipients include petrolatum, ceramides, dimethicone, glycerin, and selected fatty alcohols. The label and regulatory pathway would need to avoid unsupported therapeutic claims.

No-touch spray

A spray could address consumer reluctance to touch wounds. Commercial value would be highest in travel, workplace, sports, and household first-aid channels. The spray must control dose per actuation and avoid inhalation exposure.

Pediatric and sensitive-skin positioning

A fragrance-free, dye-free, low-residue product with a soft tube and precise dosing could target caregivers. Claims must remain within permitted OTC labeling and should not imply treatment of serious infection.

How strong is the patent estate for Triple Antibiotic?

The baseline patent estate is weak for the core product and potentially moderate for a genuinely differentiated delivery system.

Patent subject	Relative strength	Commercial value
Three active ingredients alone	Low	Minimal
Conventional petrolatum ointment	Low	Minimal
New cream or hydrogel architecture	Moderate	Depends on claim breadth and data
Controlled-release or film-forming system	Moderate to high	Potentially meaningful
Active-dispersion manufacturing process	Moderate	Useful if difficult to design around
Unit-dose container system	Low to moderate	Supports channel differentiation
Trade dress and trademark	Moderate to high commercially	Important for consumer products
Proprietary excipient supplier relationship	Moderate as know-how	Can improve cost and quality

Patent value would depend on claim scope, enablement, freedom-to-operate analysis, and whether competitors can achieve equivalent performance through different excipients.

What generic entry risks exist for Triple Antibiotic?

Generic entry risk is high because:

1. The active ingredients are established.
2. The product is generally OTC.
3. Basic ointment technology is widely available.
4. The category lacks strong composition-of-matter protection.
5. Consumers can substitute store-brand products readily.
6. Retailers often prioritize price and shelf turnover.

Brand owners can reduce substitution through packaging, clinical-quality positioning, differentiated sensory characteristics, unit-dose convenience, and retailer-specific products. These measures support market share but do not create the same legal barrier as a strong patent.

What patent litigation or Paragraph IV challenges affect Triple Antibiotic?

Paragraph IV litigation is not the central competitive risk for conventional OTC Triple Antibiotic products. Because the category is typically marketed under the OTC monograph pathway, competition does not usually follow the prescription-drug sequence of ANDA filing, Orange Book certification, and Paragraph IV litigation.

Litigation risk is more likely to involve:

• Trademark infringement.
• Trade-dress copying.
• False or misleading product claims.
• Lanham Act disputes.
• Product-liability claims involving allergic reactions.
• Patent disputes over a novel cream, gel, spray, or packaging system.
• Contract disputes with contract manufacturers or excipient suppliers.

A company developing a new delivery system should conduct a freedom-to-operate review across formulation, process, packaging, and branding rights. The active ingredients themselves are unlikely to be the principal patent obstacle.

How does Triple Antibiotic compare with competing topical products?

Product category	Main actives	Excipient opportunity	Patent barrier	Main commercial issue
Triple antibiotic	Bacitracin, neomycin, polymyxin B	Ointment, cream, spray, barrier repair	Low for basic products	Sensitization and commoditization
Bacitracin-only	Bacitracin	Simple ointment and unit dose	Low	Narrower antibacterial positioning
Double antibiotic	Bacitracin and polymyxin B	Lower active complexity	Low	Potentially improved tolerability versus neomycin-containing products
Mupirocin prescription ointment	Mupirocin	Prescription ointment and cream	Historically stronger, now largely mature	Prescription access and resistance management
Povidone-iodine topical	Povidone-iodine	Solution, ointment, scrub	Low for basic products	Staining and tissue-tolerance concerns
Silver-based wound products	Silver compounds	Foam, hydrogel, alginate, dressing systems	Variable	Higher cost and specialized wound-care use

A double-antibiotic product may offer a commercial alternative for consumers concerned about neomycin sensitization. A Triple Antibiotic product must therefore compete on convenience, price, and perceived broad coverage rather than on exclusivity alone.

What manufacturing and IP barriers affect Triple Antibiotic?

The principal manufacturing barrier is achieving reproducible distribution of low-dose antibiotic actives in a semi-solid base. Important controls include:

• Raw-material particle size.
• Mixing order and shear.
• Temperature during incorporation.
• Deaeration.
• Homogeneity testing.
• Microbial control.
• Filling accuracy.
• Tube and seal compatibility.
• Stability under temperature cycling.

For water-containing products, preservative performance and emulsion stability become major barriers. For sprays, valve performance, dose uniformity, clogging resistance, and container pressure are central.

These capabilities can create practical barriers even where patent protection is weak. A process that consistently produces stable, non-gritty, non-separating product may be protected more effectively through trade secrets than through narrow formulation claims.

What licensing deals are relevant to Triple Antibiotic?

Licensing opportunities are more likely to involve excipient technology, packaging, delivery devices, and consumer-health brands than the antibiotic actives.

Potential deal structures include:

• Licensing a film-forming polymer platform.
• Acquiring rights to a low-irritation cream base.
• Co-developing a preservative-free unit-dose package.
• Licensing a metered spray valve.
• Contract manufacturing with quality and territory restrictions.
• Private-label supply agreements with retailers.
• Brand licensing for regional OTC distribution.

The most valuable deal asset would be a delivery system with demonstrated stability and a clear regulatory path. A generic license to the active ingredients would have limited strategic value.

What geographic opportunities exist for Triple Antibiotic products?

The United States offers a relatively clear OTC monograph pathway and a large self-care market. Canada, Europe, Australia, and Asian markets apply different rules to topical antibiotics, and some jurisdictions impose tighter controls because of antimicrobial resistance and sensitization concerns.

International expansion requires review of:

• Permitted active ingredients.
• Maximum concentrations.
• OTC versus prescription classification.
• Required local clinical or quality data.
• Label language.
• Import and manufacturing requirements.
• Antibiotic stewardship policies.
• Local trademark availability.

A single global formulation may not be commercially or regulatorily optimal. The U.S. product can be built around OTC first aid, while other markets may favor antiseptic, wound-care, or prescription positioning.

Key Takeaways

• Triple Antibiotic is generally a topical OTC combination of bacitracin zinc, neomycin sulfate, and polymyxin B sulfate.
• Basic ointment products have weak patent protection because the actives and conventional vehicles are longstanding.
• The best excipient opportunities are lighter ointments, low-sensitization systems, creams, hydrogels, sprays, and unit-dose packages.
• Anhydrous petrolatum systems offer lower preservation risk and simpler manufacturing.
• Water-containing formulations offer better sensory differentiation but require stronger stability and microbial controls.
• Orange Book and Paragraph IV strategies are usually less important than trademark, trade dress, process, and formulation protection.
• Neomycin and bacitracin sensitization risk creates an opportunity for carefully positioned low-irritation or double-antibiotic alternatives.
• The highest-value IP is likely to come from delivery systems, manufacturing know-how, packaging, and validated performance data.
• Revenue exposure for individual Triple Antibiotic products is generally not separately disclosed by consumer-health companies.
• Generic and private-label substitution risk is high for conventional products.

FAQs

Can excipients reduce allergic reactions to Triple Antibiotic?

They can reduce irritation caused by fragrance, preservatives, or unsuitable bases, but they cannot eliminate sensitization caused by bacitracin or neomycin. An excipient strategy should prioritize fragrance-free, dye-free, low-impurity materials and transparent labeling.

Is a preservative-free Triple Antibiotic cream commercially feasible?

It is feasible but technically more demanding than an anhydrous ointment. The product would need a validated microbial-control strategy, suitable packaging, and stability data demonstrating that the absence of conventional preservatives does not create unacceptable contamination risk.

Can Triple Antibiotic be formulated with ceramides?

Yes. Ceramides, cholesterol, fatty acids, dimethicone, and humectants could support a barrier-repair positioning. The formulation must preserve antibiotic stability and avoid claims that move the product outside the applicable OTC framework.

Is a Triple Antibiotic spray more patentable than an ointment?

Potentially. A spray may support claims directed to dose uniformity, film formation, active stabilization, valve design, or no-touch delivery. Patent strength would depend on technical differentiation and the ability to prevent easy design-around.

Why might a double-antibiotic product outperform Triple Antibiotic?

A double-antibiotic product may appeal to consumers and clinicians seeking to avoid neomycin because of contact-sensitization concerns. It may also have a simpler formulation and lower active-load complexity, although it provides a different antibacterial spectrum and positioning.

References

1. National Library of Medicine. (n.d.). DailyMed: Neosporin original ointment label. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2020). Topical antimicrobial drug products for over-the-counter human use: Final administrative order. 21 C.F.R. Part 333.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. Kenvue Inc. (2024). Annual report and consumer health product portfolio disclosures. U.S. Securities and Exchange Commission.